
<html>

<head>
<title></title>
</head>

<body LINK="#0000ff" VLINK="#7f007f">
<b>

<p ALIGN="CENTER">CLINICAL DATA NAMES RANDAL J. KIRK NEW CHAIRMAN</p>
</b><font SIZE="2">

<p ALIGN="JUSTIFY">NEWTON, MA &#150; December 22, 2004, Clinical Data, Inc. (NASDAQ:CLDA)
announced today that its Board of Directors has named Randal J. Kirk to the position of
Chairman of the Board effective as of December 16, 2004. Previously, Israel M. Stein,
M.D., Clinical Data&#146;s President and Chief Executive Officer, had also served in the
position of Chairman of the Board.</p>

<p ALIGN="JUSTIFY">Mr. Kirk, who is the Chairman and Senior Managing Director of Third
Security, LLC, a private investment and advisory firm based in Radford, Virginia, became a
Director of Clinical Data in September 2002. Mr. Kirk also serves as Chairman, President,
and Chief Executive Officer of New River Pharmaceuticals Inc. (NASDAQ:NRPH), a specialty
pharmaceutical company; and as a director of several other firms. Mr. Kirk also serves on
the Board of Visitors of Radford University, as a member of the Board of Directors of the
Radford University Foundation, Inc., as a member of the Virginia Bioinformatics Institute
Policy Advisory Board, and on the Board of Directors of Tek.Xam Foundation.</p>

<p ALIGN="JUSTIFY">&quot;As the Chairman, I will bring to bear the full perspective of the
Board in guiding the Company and assisting Dr. Stein in realizing the Company&#146;s
future potential. Dr. Stein, as President and CEO, as his past success has demonstrated,
will continue to be responsible for executing our strategy and managing the company&#146;s
operations,&quot; Mr. Kirk noted. </p>

<p ALIGN="JUSTIFY">Dr. Stein commented, &quot;In his new role, RJ will be able to play a
more active part in supporting the senior management team in the execution of our
company&#146;s overall strategic objectives. We welcome the strong track record of success
RJ brings to the position of Clinical Data&#146;s Chairman as we look toward executing new
strategic initiatives in the coming year. I look forward to continuing our close
collaboration with RJ in his new role in helping Clinical Data achieve new levels of
success.&quot;</p>

<p ALIGN="JUSTIFY">Clinical Data, Inc., through its domestic and foreign subsidiaries,
focuses on the needs of physician offices and smaller clinical laboratories. The Company
provides a complete range of products and consulting services to the growing physician
office laboratory market and offers blood chemistry instrumentation and diagnostic assays
to clinics and small hospitals worldwide. </p>
</font><font SIZE="1"><i>

<p ALIGN="JUSTIFY">Except for any historical information contained in this press release,
the matters discussed herein constitute forward looking statements within the meaning of
the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as
amended, that involve risks and uncertainties. Actual results could differ materially from
those expressed in such statements and readers are referred to the Company&#146;s SEC
reports and filings, including the Company&#146;s Annual Report on Form 10-KSB for the
year ended March 31, 2004, filed with the SEC on June 28, 2004, and the Company&#146;s
Quarterly Reports on Form 10-QSB for quarters ended June 30, 2004, and September 30, 2004,
filed with the SEC respectively on August 12, 2004, and November 12, 2004.</p>
</i></font>
</body>
</html>

